Treating and Managing LAL-D

Managing LAL-D has been transformed by the development of enzyme replacement therapy (ERT). While diets and other medications were once the only tools available, we now have a treatment that targets the root cause of the disease ^[1][2].

The Standard of Care: Sebelipase Alfa (Kanuma)

Sebelipase alfa (brand name Kanuma) is the only FDA-approved, disease-modifying treatment for LAL-D ^[1]. Because your body cannot produce enough of the LAL enzyme, this medication provides a lab-made version of that enzyme to do the work for you ^[2][3].

• How it is given: It is administered as an intravenous (IV) infusion—a liquid medication delivered through a needle or port directly into a vein ^[2].
• The Schedule: For most children and adults, infusions occur once every other week ^[2][4]. For infants with severe, rapidly progressing disease, the schedule may be more frequent, such as once a week, to provide more constant enzyme support ^[5].
• What it does: Once in the body, the enzyme travels to your cells’ lysosomes and begins breaking down the “lipid logjam” ^[6]. This helps lower “bad” cholesterol (LDL), raise “good” cholesterol (HDL), and reduce the amount of fat stored in the liver ^[6][4]. Over time, this treatment can even help reverse liver scarring (fibrosis), even in patients with advanced disease ^[7].

What to Expect on Infusion Day & Safety

Infusions typically take a couple of hours. During this time, nurses will regularly check your or your child’s vital signs (heart rate, blood pressure, temperature) to ensure safety.

While highly effective, enzyme replacement therapies carry a known risk of severe allergic reactions, including hypersensitivity and anaphylaxis, during or shortly after the infusion ^[8]. Because of this risk, you will be closely monitored, and doctors frequently use premedications (such as antihistamines or fever-reducers) beforehand to help prevent these immune reactions.

Supportive Dietary Management

It is critical to consult a specialized metabolic dietician. While a low-lipid diet is recommended to support the body, it requires careful professional guidance. For infants with the severe form, standard dietary fats can be incredibly harmful, and specific medical formulas (such as those using medium-chain triglycerides or MCT oils) are strictly required ^[9][10].

• Statins and Lipid-Lowering Drugs: Many patients take these before being diagnosed with LAL-D ^[11]. However, statins only lower the cholesterol your body makes; they cannot touch the fat already trapped inside your cells ^[12]. Your doctor should re-evaluate these medications once you start ERT ^[11].

Intensive Options for Severe Cases

In certain situations, more intensive medical interventions may be necessary:

• Liver Transplant: If LAL-D has already caused the liver to fail, a transplant may be required ^[13]. However, a liver transplant is not a cure. Because the genetic defect is still in your other cells, immune cells (macrophages) circulating in the blood that lack the enzyme will eventually settle in the new liver, causing the disease to recur ^[13][14].
• Stem Cell Transplant (HSCT): This has been used in the past for infants with the most severe form of the disease ^[15]. It is a very high-risk procedure and is now less common because of the success of Sebelipase alfa ^[1][5].

Vetting Your Care Team

LAL-D is an ultra-rare disease, and it is important that your doctors are familiar with the latest standards. Consider asking:

• “How many other LAL-D patients have you treated?”
• “Are you familiar with the dosing protocols for Sebelipase alfa in both infants and adults?”
• “Do we have a metabolic specialist or biochemical geneticist on our team?”
• “If I have a reaction during an infusion, what is our exact protocol for managing it?” ^[8]